
EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013


Business today/YES bank Excellence Awards-2013

Eris Lifesciences Ltd.

Date: 5th November, 2019

To **The Department of Corporate Services** **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	**To** **National Stock Exchange of India Limited** Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	**Symbol: ERIS**

SUBJECT: INTIMATION OF SCHEDULE OF ANALYST & INVESTOR CALL PURSUANT TO REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)

Dear Sir/Madam,

This is further to our letter dated 24th October, 2019 intimating about the date of the Board of Directors Meeting to inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30th September, 2019.

We wish to inform that pursuant to regulation 30 and other applicable regulations, if any, of the SEBI LODR, 2015 the Company will hold a conference call for analysts and investors on Thursday, 7th November, 2019. The details of the said call are attached herewith and also available on Company's website.

Thanking you.

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary and Compliance Officer
Membership No.: A26493

Encl.:a/a

The Senior Management Team of

Eris Lifesciences Limited

Cordially invites you to its

Earnings Conference Call

To discuss the financial and operational performance for

Q2 & H1 FY20

Day/Date: **Thursday, 7th November 2019**

Time: **4:30 PM, IST**

Access Numbers	
Primary Number:	+91 22 6280 1472
	+91 22 7115 8839
Toll Free Number:	USA: 1 866 746 2133
	UK: 0 808 101 1573
	Singapore: 800 101 2045
	Hong Kong: 800 964 448

We look forward to your participation

RSVP:

Strategic Growth Advisors Private Limited
Neha Shroff: +91 22 6114 6603